1700-P: Weight Reduction Is Associated with Improved Quality of Life in Participants with Obesity or Overweight and Type 2 Diabetes—Results from Phase 3 SURMOUNT-2 Trial

Introduction ≥10%, 3.95; ≥15%, 4.74; ≥20%, 4.63) and Mental Health (norm-based) (≥5%, 1.65; ≥10%, 1.75; ≥15%, 2.34; ≥20%, 2.63). Adults who achieved most higher weight targets showed greater improvements from baseline in IWQOL-Lite-CT total score (≥5%, 14.68; ≥10%, 15.45; ≥15%, 18.53; ≥20%, 20.10), and Physical and Psychosocial composite scores. Greater improvement from baseline in EQ-5D VAS scores was observed in adults meeting greater weight reduction targets (≥5%, 9.75; ≥10%, 10.60; ≥15%, 12.33; ≥20%, 12.67). Conclusion: Weight reduction in tirzepatide-treated adults was associated with improvement in all HRQoL domains, including physical function and mental health. Adults who lost the most weight generally showed the greatest HRQoL improvements. Disclosure T. Hunter Gibble: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. D. Cao: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. M.X. Zhang: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. N. Xavier: Employee; Eli Lilly and Company. J. Poon: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. Funding Eli Lilly and Company